Skip to main content
Eutilex Co.,Ltd. logo

Eutilex Co.,Ltd. — Investor Relations & Filings

Ticker · 263050 ISIN · KR7263050007 KO Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2023-02-06 Capital/Financing Update
Country KR South Korea
Listing KO 263050

About Eutilex Co.,Ltd.

https://www.eutilex.com/en/

Eutilex Co., Ltd. is a biotechnology company focused on the research and development of immunotherapeutics for cancers and autoimmune diseases. The company's core approach involves selecting targets that enhance or suppress human immune responses. Its pipeline is centered on three primary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Key development programs include adoptive T-cell therapies, such as those based on 4-1BB cytotoxic T lymphocytes (CTL), and various immunomodulatory antibody therapeutics designed to treat a range of incurable diseases.

Recent filings

Filing Released Lang Actions
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from Eutilex regarding the acquisition of convertible bonds before maturity (a debt buyback). It details the bond series, acquisition amount, reason (put option exercise), and future treatment (cancellation). This falls under capital structure changes and financing updates, specifically related to debt management.
2023-02-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of an executive (Han Jung-hoon) of Eutilex due to his resignation. This type of filing is a standard regulatory requirement for reporting insider share ownership changes, which falls under the 'Director's Dealing' category.
2023-01-06 Korean
투자판단관련주요경영사항(EU103(항VSIG4 항체치료제) 고형암 대상 제1상 임상시험계획서(IND) 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Eutilex regarding the submission of an Investigational New Drug (IND) application for a clinical trial (EU103). It follows the standard format for 'Major Management Matters' (주요경영사항) in the Korean stock market, which is a mandatory disclosure of significant corporate events. Since it does not fit into specific categories like M&A, dividends, or share buybacks, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2023-01-02 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and the closure of the shareholder register for the purpose of holding an upcoming Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the administrative procedure required for the meeting. Given it is a standard regulatory notification regarding corporate governance procedures, it fits best under the RNS category.
2022-12-16 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Eutilex Co., Ltd.' covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial statements, business operations, management analysis, and governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory disclosure from Eutilex regarding the acquisition of convertible bonds before maturity (specifically due to a put-option exercise). This falls under capital structure changes and financing updates, specifically related to debt instruments. Given the specific nature of bond buybacks/acquisitions, it aligns best with the Capital/Financing Update category.
2022-11-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.